Macrophage migration inhibitory factor (MIF) inhibitor 4-IPP downregulates stemness phenotype and mesenchymal trans-differentiation after irradiation in glioblastoma multiforme.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 31 05 2021
accepted: 31 08 2021
entrez: 13 9 2021
pubmed: 14 9 2021
medline: 24 11 2021
Statut: epublish

Résumé

Radiation therapy is among the most essential treatment methods for glioblastoma multiforme (GBM). Radio-resistance and cancer stem cell properties can cause therapeutic resistance, cancer heterogeneity, and poor prognoses in association with GBM. Furthermore, the GBM subtype transition from proneural to the most malignant mesenchymal subtype after radiation therapy also accounts for high resistance to conventional treatments. Here, we demonstrate that the inhibition of macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (DDT) by 4-iodo-6-phenylpyrimidine (4-IPP), a dual inhibitor targeting MIF and DDT, downregulates stemness phenotype, intracellular signaling cascades, mesenchymal trans-differentiation, and induces apoptosis in proneural glioma stem cells (GSCs). In an analysis of The Cancer Genome Atlas, high MIF and DDT expression were associated with poor prognosis. GSC growth was effectively inhibited by 4-IPP in a time- and dose-dependent manner, and 4-IPP combined with radiation therapy led to significantly reduced proliferation compared with radiation therapy alone. The expression of stemness factors, such as Olig2 and SOX2, and the expression of pAKT, indicating PI3K signaling pathway activation, were decreased in association with both 4-IPP monotherapy and combination treatment. The expression of mesenchymal markers, TGM2 and NF-κB, and expression of pERK (indicating MAPK signaling pathway activation) increased in association with radiation therapy alone but not with 4-IPP monotherapy and combination therapy. In addition, the combination of 4-IPP and radiation therapy significantly induced apoptosis compared to the monotherapy of 4-IPP or radiation. In vivo results demonstrated a significant tumor-suppressing effect of 4-IPP when combined with radiation therapy. Collectively, our results showed that the targeted inhibition of MIF and DDT has the potential to strengthen current clinical strategies by enhancing the anticancer effects of radiation therapy.

Identifiants

pubmed: 34516577
doi: 10.1371/journal.pone.0257375
pii: PONE-D-21-14550
pmc: PMC8437287
doi:

Substances chimiques

Indoles 0
Macrophage Migration-Inhibitory Factors 0
indolepropanol phosphate 40716-80-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0257375

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

FASEB J. 2014 Nov;28(11):4961-71
pubmed: 25016026
Cell Signal. 2014 Dec;26(12):2969-78
pubmed: 25277536
J Cell Biochem. 2015 Nov;116(11):2504-16
pubmed: 25900216
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Stem Cells. 2016 Aug;34(8):2026-39
pubmed: 27145382
PLoS One. 2016 Jan 07;11(1):e0146482
pubmed: 26741693
J Clin Invest. 2017 Feb 1;127(2):415-426
pubmed: 28145904
Chemotherapy. 2004 Apr;50(1):43-50
pubmed: 15084806
Oncol Rep. 2016 May;35(5):2733-42
pubmed: 26935642
Cell Signal. 2017 Jun;34:110-120
pubmed: 28323005
Cancer Res. 2016 May 1;76(9):2813-23
pubmed: 26980763
Cancer Cell. 2016 Feb 8;29(2):201-13
pubmed: 26859459
Int J Oncol. 2014 Nov;45(5):1813-9
pubmed: 25174607
Biochim Biophys Acta. 2007 Aug;1773(8):1263-84
pubmed: 17126425
Int J Mol Sci. 2019 Jun 04;20(11):
pubmed: 31167470
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):E577-85
pubmed: 21817065
J Biol Chem. 2014 Feb 7;289(6):3713-23
pubmed: 24356968
Cancer Lett. 2019 Sep 10;459:30-40
pubmed: 31128213
Oncogene. 2007 Aug 2;26(35):5046-59
pubmed: 17310986
Biomed Pharmacother. 2017 Aug;92:681-689
pubmed: 28582760
Sci Rep. 2019 Feb 27;9(1):2905
pubmed: 30814573
Cancer Lett. 2017 Apr 1;390:176-187
pubmed: 28007636
Cell Death Differ. 1999 Feb;6(2):99-104
pubmed: 10200555
Cancer Cell. 2013 Sep 9;24(3):331-46
pubmed: 23993863
Cancer Immunol Immunother. 2016 Dec;65(12):1465-1476
pubmed: 27629595
Anticancer Res. 2019 Feb;39(2):597-607
pubmed: 30711935
Front Oncol. 2018 Nov 08;8:503
pubmed: 30467536
Cell. 2017 Apr 20;169(3):381-405
pubmed: 28431241
Cancer Res. 2017 Sep 15;77(18):4973-4984
pubmed: 28754668
Acta Neuropathol. 2011 Sep;122(3):353-65
pubmed: 21773885
N Engl J Med. 2008 Jul 31;359(5):492-507
pubmed: 18669428
J Med Chem. 2018 Sep 27;61(18):8104-8119
pubmed: 29812929
J Neurooncol. 2012 Jan;106(1):43-51
pubmed: 21725855
Front Oncol. 2012 Jun 04;2:58
pubmed: 22675673

Auteurs

Shin Heon Lee (SH)

Department of Medicine, Graduate School, Chung-Ang University, Seoul, Korea.
Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Hyung Joon Kwon (HJ)

Department of Cancer Control and Population Health, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.

Saewhan Park (S)

Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.

Chan Il Kim (CI)

Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.

Haseo Ryu (H)

Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.

Sung Soo Kim (SS)

Department of Clinical Research, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Graduate School of Cancer Science and Policy R&D Foundation, National Cancer Center, Goyang, Korea.

Jong Bae Park (JB)

Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Department of Clinical Research, Research Institute and Hospital, National Cancer Center, Goyang, Korea.

Jeong Taik Kwon (JT)

Department of Neurosurgery, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH